CREATE Medicines

CREATE Medicines is a clinical-stage biotechnology company focused on in vivo multi-immune programming. The company was founded in 2019 by Daniel Getts, who serves as the Chief Executive Officer. CREATE is developing a proprietary mRNA-LNP (messenger RNA-lipid nanoparticle) platform designed to program immune cells directly within the patient's body. This approach aims to provide scalable, off-the-shelf immunotherapies that can be administered in repeat doses.

The company’s core technology avoids the complex and costly ex vivo (outside the body) cell manipulation that is characteristic of many current cell therapies. Instead, it delivers mRNA payloads to immune cells in vivo to reprogram them for therapeutic purposes, such as creating CAR (Chimeric Antigen Receptor) therapies to fight diseases. The firm's pipeline is concentrated on developing treatments for cancer, autoimmune disorders, and fibrosis.

CREATE Medicines has secured significant funding to advance its research and clinical programs. The company raised $12 million in a seed round in September 2019, followed by a Series A round in January 2021. In May 2023, it completed a Series A2 financing of $73 million, bringing its total funds raised to $135 million. Its investors include ARCH Venture Partners, Moore Strategic Ventures, and 8VC, among others. The business model is centered on advancing its proprietary platform technology through clinical trials to validate its safety and efficacy, with the ultimate goal of commercializing its in vivo immunotherapies. This may involve forming strategic partnerships with larger pharmaceutical companies to leverage their development and commercialization expertise.

Keywords: in vivo immune programming, mRNA-LNP platform, RNA therapeutics, CAR-T therapies, off-the-shelf immunotherapy, cancer treatment, autoimmune disease therapy, fibrosis treatment, clinical-stage biotech, drug discovery, myeloid cells, gene therapy, immunotherapy, venture capital-backed, cell therapy